Immune checkpoint inhibitor related enterocolitis

Research output: Contribution to journalArticlepeer-review


Immune checkpoint inhibitors (ICI) have been rapidly extended their indication in various cancer types. On the other hand, immune-related adverse event (irAE) is observed in some cases and sometime causes fatal outcome. Enterocolitis is one of the major irAE, especially in the case treated with anti-CTLA-4 antibody. Although the combination therapy of anti-CTLA-4 antibody and anti-PD-1 antibody has shown clinical benefit in some cancer types, a risk of enterocolitis is higher than monotherapy. Accumulated evidence has revealed the clinical features of enterocolitis caused by anti-CTLA-4 antibody and anti-PD-1/PD-L1 antibody. We summarize recent knowledge and discuss future perspectives.

Original languageEnglish
Pages (from-to)214-218
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Issue number2
Publication statusPublished - 2020 Feb


  • Enterocolitis
  • Immune checkpoint inhibitor
  • Immune-related adverse event

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Immune checkpoint inhibitor related enterocolitis'. Together they form a unique fingerprint.

Cite this